Eiger BioPharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary

Eiger Biopharmaceuticals

04/11/2021 21:03

* Eiger BioPharmaceuticals Inc  EIGR.OQ  reported a quarterly
adjusted loss of 65 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 56 cents per share.
* Revenue was $3.04 million​;  analysts expected $2.94 million. 
* Eiger BioPharmaceuticals Inc's reported EPS for the quarter
was a loss of 65 cents​.
* The mean earnings estimate of analysts had fallen by
about 0.7% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Eiger BioPharmaceuticals Inc shares had risen by 17.5% this
quarter and lost 36.1% so far this year.
* The company reported a quarterly loss of $22.22 million.
* Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $28.00 
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
This summary was machine generated November 4 at 09:02 p.m.
 ​All figures in US dollars unless otherwise stated